| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| BIONTECH | 8 | 13 | +1,32 % | ||
| BIOGEN | 5 | 54 | +1,79 % | ||
| ANI PHARMACEUTICALS | 5 | 5 | 0,00 % | ||
| REVOLUTION MEDICINES | 4 | 5 | +1,43 % | ||
| ATAIBECKLEY | 4 | - | +25,73 % | ||
| AMGEN | 3 | 27 | -0,55 % | ||
| COMPASS PATHWAYS | 3 | 11 | +32,46 % | ||
| BICYCLE THERAPEUTICS | 3 | 5 | -3,52 % | ||
| XENON PHARMACEUTICALS | 3 | - | 0,00 % | ||
| ASCENDIS PHARMA | 3 | - | +0,96 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17:14 | VIATRIS INC zündet - jetzt beginnt der Höhenflug! | - | Maximilian Berger | ||
| 17:10 | Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike | 4 | FiercePharma | ||
| 16:42 | Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday | 4 | Benzinga.com | ||
| 16:29 | Biogen Zooms on Deal with TJ Biopharma | 4 | Baystreet.ca | ||
| 16:22 | Oruka Therapeutics: TD Cowen bestätigt Kaufempfehlung vor wichtigen Studiendaten | 1 | Investing.com Deutsch | ||
| 16:06 | Amgen - Korrektur beendet? | Société Générale | |||
| 15:42 | Piper Sandler reiterates Overweight on BridgeBio stock at $111 | 1 | Investing.com | ||
| 15:34 | BridgeBio: Piper Sandler bestätigt "Overweight"-Rating und sieht Kurspotenzial bis 111 US-Dollar | 1 | Investing.com Deutsch | ||
| 15:34 | Is ANIP Stock Undervalued at 10x Forward Earnings and $93 Target? | 2 | Zacks | ||
| 15:34 | ANI Pharmaceuticals' 2026 Catalysts Include Gout Push and New Generics | 1 | Zacks | ||
| 15:34 | ANIP's Cortrophin Gel Surge Powers 2026 Growth Outlook | 2 | Zacks | ||
| 15:30 | AnaptysBio completes spin-off of First Tracks Biotherapeutics | 5 | Investing.com | ||
| 15:27 | Depot: AtaiBeckley hebt ab: Marvell: Alphabet bestellt, Kailera: Starkes IPO & Siemens: Macht es wie Nvidia | 391 | Markus Weingran | Siemens steigt beim Lithium-Projekt von Vulcan Energy ein. Zum einen wird der Konzern Minderheitsaktionär, zum anderen sichert man sich einen Auftrag in Höhe von 40 Millionen €. Nvidia macht diesen... ► Artikel lesen | |
| 15:24 | Arcus halts Gilead-partnered late-stage trial for lung cancer drug | 4 | Seeking Alpha | ||
| 15:18 | AnaptysBio, Inc.: Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | 77 | GlobeNewswire (Europe) | Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately... ► Artikel lesen | |
| 15:18 | Immuneering presents genetic data on atebimetinib resistance | 1 | Investing.com | ||
| 15:10 | Biogen bullish on America with Durham Bulls team up | 6 | FiercePharma | ||
| 14:54 | Canaccord raises AtaiBeckley stock price target on pricing model | 17 | Investing.com | ||
| 14:36 | Allogene Therapeutics, Inc.: Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 | 1 | GlobeNewswire (USA) | ||
| 14:34 | 10x Genomics Stock Up on Atera Launch, Spatial Biology Scale Enhanced | 1 | Zacks |